Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Sep 2nd, 4:39 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 30.19 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference
Clene (NASDAQ: CLNN) announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host one-on-one investor meetings.
Via Investor Brand Network · September 2, 2025
Piedmont, SC - September 1, 2025 - Palmetto Complete Auto Care, a trusted provider of auto repair in Piedmont, SC, is proud to announce the approaching launch of its first website. This milestone is an important step in the shop’s commitment to offering convenience, clear communication, and exceptional service.
Via Get News · September 1, 2025
The Exclusive Transfer, Bangkok’s leading provider of luxury airport transportation, is honored to announce that it has been awarded Tripadvisor’s “Most Trusted Airport Transfer Service” recognition. This award is a testament to the company’s dedication to offering travelers a seamless, safe, and reliable experience when arriving at or departing from Suvarnabhumi and Don Mueang airports.
Via AB Newswire · September 1, 2025
September 1, 2025 - Precision Motorworks, a full-service auto repair shop in St. Charles, IL, proudly announces a key milestone in its continued growth: the installation of permanent exterior signage at its West Main Street location at 2010 W Main St, St. Charles, IL 60174. This upgrade is more than just a visual enhancement; it represents the shop’s continued commitment to European auto repair and its dedication to delivering high-end service to the local community.
Via Get News · September 1, 2025
Superior Replacement Windows, a locally owned and operated Phoenix windshield replacement company serving Maricopa County since 2010, has been awarded the prestigious "Best in Phoenix" recognition among top window glass replacement companies. This award highlights the company's exceptional customer satisfaction across their comprehensive auto glass, residential glass, and commercial glass services, with particular recognition for their specialized expertise in luxury vehicle windshield replacement.
Via AB Newswire · August 30, 2025
BioMedNewsBreaks — Zevra Therapeutics, Inc. (NASDAQGS: ZVRA) to Present New MIPLYFFA Data at ICIEM, Poster Earns Best Poster Award
Zevra Therapeutics (NASDAQGS: ZVRA), a commercial-stage company focused on therapies for rare diseases, announced that four posters on MIPLYFFA (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), held Sept. 2-6, 2025, in Kyoto, Japan. MIPLYFFA, approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC), will be highlighted in a Best Poster award-winning presentation (#BP-19) detailing its unique mechanism of action targeting NPC pathophysiology. Additional presentations will feature positive new data from a pediatric substudy in patients younger than two years old and a prespecified efficacy analysis in patients on miglustat who switched from placebo to MIPLYFFA.
Via Investor Brand Network · August 29, 2025
Health Care Titans are Filing for Bankruptcy in America
All sectors have their share of bankruptcies every year, but the health care sector is experiencing these filings in a concerning way; major players are going under as the weight of financial headwinds takes a huge toll. The health care system has variously been described as being in the throes of a crisis, and companies within the system are no exception.
Via Investor Brand Network · August 29, 2025
BioMedNewsBreaks — Propanc Biopharma, Inc. (NASDAQ: PPCB) Closes $4 Million Public Offering
Propanc Biopharma (NASDAQ: PPCB) announced the closing of its underwritten public offering of 1,000,000 shares of common stock at $4.00 per share, generating $4 million in gross proceeds before deducting underwriting discounts and expenses. The Company also granted the underwriter a 45-day option to purchase up to 150,000 additional shares. The shares commenced trading on the Nasdaq Capital Market on Aug. 15, 2025, with the offering closing on Aug. 18, 2025. D. Boral Capital LLC and Craft Capital Management LLC acted as book running managers for the offering.
Via Investor Brand Network · August 29, 2025
Secure Locks Expands Duplicate Car Key Services for Drivers in Chicago
Chicago, IL - August 28, 2025 - Losing a car key isn’t the only way drivers end up stranded. Many Chicago residents face stressful delays simply because they don’t have a spare key. To meet this growing need, Secure Locks now offers reliable duplicate car key services for a wide range of vehicle makes and models, helping drivers avoid emergencies before they happen.
Via AB Newswire · August 28, 2025
Secure Locks Expands Car Key Replacement Services for Drivers in Chicago
Chicago, IL - August 28, 2025 - Losing a car key can leave drivers stranded and frustrated, especially in a busy city like Chicago. For local residents, Secure Locks has become the dependable solution, providing professional car key replacement services for a wide range of vehicle makes and models. From traditional keys to advanced smart keys and fobs, the company’s technicians are trained to handle replacements quickly, accurately, and at the roadside when needed.
Via AB Newswire · August 28, 2025
The global financial landscape is bracing for a significant shift as major central banks, including the U.S. Federal Reserve, the European Central Bank, and the Bank of England, signal an anticipated move towards monetary policy easing through interest rate cuts. This pivot, emerging after a period of aggressive tightening
Via MarketMinute · August 28, 2025
Study Explains Why Blood Clotting is Common in IBD Patients
About 3 million people in the U.S. live with irritable bowel disease (IBD), and its prevalence is rising. Unfortunately, there isn’t a cure for the condition at the moment. Many individuals with IBD develop clots in their blood and these can result in strokes and heart attacks . Now a new study has discovered possible reasons why these clots are common and suggests a possible way to address this problem while also reducing inflammation.
Via Investor Brand Network · August 28, 2025
HeartBeam Inc. (NASDAQ: BEAT) Advances Patient Convenience with At-Home ECG Technology
Clinicians are increasingly recognizing the value of accurate at-home electrocardiogram (“ECG”) capture, a development that is shaping the future of cardiac care. HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation with its FDA-cleared HeartBeam System, the first cable-free ECG device that captures the heart’s signals from 3 distinct directions and is designed to be a groundbreaking solution for at-home detection and monitoring of arrhythmias.
Via Investor Brand Network · August 27, 2025
Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Unveils Comprehensive Brand Identity Transformation to Position Company for Commercial Launch
As Izotropic (CSE: IZO) (OTCQB: IZOZF) positions itself to capture a share of the $8.7 billion global breast imaging market projected by 2030 ( ibn.fm/tRIr4 ), the company has unveiled a strategic brand transformation that signals its readiness to commercialize two decades of breakthrough medical research. Izotropic holds exclusive global licensing rights to revolutionary breast CT technology and is advancing its flagship IzoView Breast CT Imaging System from proven science to real-world medical impact, offering what could be the first-in-class solution for more accurate breast cancer screening and diagnosis.
Via Investor Brand Network · August 26, 2025
Blocking Glioblastoma-Triggered Brain Damage Could Slow the Aggressive Tumor’s Growth
According to new research conducted by a team at University College London, blocking the brain damage caused by glioblastoma could keep the patient’s brain working better for a much longer time and also slow the pace at which the tumor grows .
Via Investor Brand Network · August 26, 2025
Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to tackle medical challenges where conventional treatments have failed to deliver meaningful solutions, recently reported on its progress so far this year ( https://ibn.fm/1dhGj ).
Via Investor Brand Network · August 26, 2025
A major tax benefit is disappearing, and some of the biggest automakers could be affected.
Via The Motley Fool · August 24, 2025
Pioneering Therapy Could Slow the Effects of Aging
A new groundbreaking therapy could slow down or even reverse aging by recharging body cells with new “batteries” that provide new energy for bodily function. The new therapy utilizes mitochondria from the placenta of infants, which are then transplanted into older people or those suffering from diseases that are currently regarded as incurable.
Via Investor Brand Network · August 22, 2025
European financial markets are currently experiencing a period of mixed performance, reflecting a complex interplay of economic data, geopolitical shifts, and the recent announcement of a US-EU trade deal framework. While the pan-European STOXX 600 index has shown slight gains, and the UK's FTSE 100 has seen increases, major national
Via MarketMinute · August 21, 2025
In a significant move poised to reshape global trade dynamics, the United States and the European Union have unveiled a new "Framework on an Agreement on Reciprocal, Fair, and Balanced Trade." Announced on August 21, 2025, this foundational agreement aims to invigorate one of the world's largest trade and investment
Via MarketMinute · August 21, 2025
Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), released its second quarter 2025 financial results and provided an update on its clinical programs. The company emphasized progress toward an NDA submission for its lead asset CNM-Au8 in ALS, expected in the fourth quarter of 2025 ( https://ibn.fm/PiKqu ).
Via Investor Brand Network · August 21, 2025
Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors
Scientists at Columbia University have engineered a cancer treatment that leverages bacteria to smuggle cancer-killing viruses into tumors in a method that sidesteps the defenses of the immune system. This groundbreaking approach utilizes two vital weapons against the cancer; the bacteria are drawn to cancer cells, and the viruses inside the bacteria deliver the killer blow to the tumor cells after being delivered there by the bacteria.
Via Investor Brand Network · August 21, 2025
If you drive a BMW, you already know — the right parts make all the difference. Whether it’s a complete engine, a pair of BMW headlights, or a small but crucial sensor, the quality and authenticity of that part determine how your car feels, drives, and lasts.
Via AB Newswire · August 20, 2025
BioMedNewsBreaks — BioAdaptives, Inc. (OTCMKTS: BDPT) Receives WADA-Compliant Certification for MyndMed(TM) From TruShield(TM)
BioAdaptives (OTCMKTS: BDPT), a developer of natural health and performance supplements, said its nootropic formula MyndMed(TM) was certified clean by TruShield(TM) Laboratory Services following testing for World Anti-Doping Agency compliance. TruShield, whose protocols are trusted by professional sports organizations including the UFC(R), confirmed MyndMed contains no banned substances and meets safety standards for competitive athletes. BioAdaptives said the clearance supports integration of MyndMed into the UFC’s approved supplement pool, providing fighters with cognitive performance, focus and reaction-time support without risk of anti-doping violations.
Via Investor Brand Network · August 20, 2025